Provided by Tiger Trade Technology Pte. Ltd.

Anaptysbio Inc

45.78
+0.83001.85%
Pre-market: 45.40-0.3800-0.83%04:59 EST
Volume:485.19K
Turnover:22.43M
Market Cap:1.27B
PE:-15.92
High:47.86
Open:44.56
Low:43.90
Close:44.95
52wk High:47.86
52wk Low:12.21
Shares:27.69M
Float Shares:14.25M
Volume Ratio:1.27
T/O Rate:3.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.8757
EPS(LYR):-5.1170
ROE:-308.02%
ROA:-4.23%
PB:-43.09
PE(LYR):-8.95

Loading ...

AnaptysBio :  Barclays Initiates Coverage With Overweight Rating and Target Price $78

THOMSON REUTERS
·
Oct 13

Barclays Initiates AnaptysBio at Overweight With $78 Price Target

MT Newswires Live
·
Oct 13

AnaptysBio Initiated at Overweight by Barclays

Dow Jones
·
Oct 13

Analysts Offer Insights on Healthcare Companies: AnaptysBio (ANAB), Stoke Therapeutics (STOK) and Certara (CERT)

TIPRANKS
·
Oct 09

Eric J. Loumeau, Chief Legal Officer, Reports Disposal of AnaptysBio Inc. Common Shares

Reuters
·
Oct 02

BUZZ-U.S. STOCKS ON THE MOVE-Nike, Occidental Petroleum, Carvana

Reuters
·
Oct 01

CORRECTED-BUZZ-AnaptysBio climbs after Leerink raises PT on investor-friendly spinoff plans (Sept 30)

Reuters
·
Oct 01

AnaptysBio's Split Announcement Seems 'Awkward' Amid Clinical Activities, Truist Securities Says

MT Newswires Live
·
Sep 30

AnaptysBio Inc : Leerink Partners Raises Target Price to $37 From $32

THOMSON REUTERS
·
Sep 30

Guggenheim Sticks to Their Buy Rating for AnaptysBio (ANAB)

TIPRANKS
·
Sep 30

AnaptysBio Price Target Maintained With a $45.00/Share by Wedbush

Dow Jones
·
Sep 30

AnaptysBio (ANAB) Gets a Hold from Truist Financial

TIPRANKS
·
Sep 30

BRIEF-Anaptys Announces Intent To Separate Biopharma Operations From Substantial Royalty Assets By Year-End 2026

Reuters
·
Sep 30

AnaptysBio Considering Splitting Into Two Cos.

Dow Jones
·
Sep 30

AnaptysBio trading resumes

TIPRANKS
·
Sep 30

AnaptysBio announces intent to separate into two publicly traded companies

TIPRANKS
·
Sep 30

AnaptysBio to Split Into Two Public Companies, Separating Biopharma Operations and Royalty Assets by End of 2026

Reuters
·
Sep 30

AnaptysBio to Present Overview of ANB033 CD122 Antagonist at Upcoming Virtual Investor Event

Reuters
·
Sep 30

Anaptys Announces Intent to Separate Biopharma Operations From Substantial Royalty Assets by Year-End 2026

THOMSON REUTERS
·
Sep 30

AnaptysBio Inc - Daniel Faga Anticipated to Be CEO of Biopharma Co

THOMSON REUTERS
·
Sep 30